Do Corticosteroid Injections During Total Knee Replacement Improve Early Clinical Results?

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2007 by New Lexington Clinic.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
St. Joseph's Health Care London
Information provided by:
New Lexington Clinic
ClinicalTrials.gov Identifier:
NCT00492973
First received: June 25, 2007
Last updated: NA
Last verified: June 2007
History: No changes posted
  Purpose

Prior to surgery, a pharmacist will randomly assign participating patients to one of two groups. One group will get an injection in the knee during surgery that contains medications to limit pain and an antibiotic. A second group will get an injection in the knee during surgery that contains the same pain medications and antibiotic along with a corticosteroid to control inflammation. Corticosteroids are anti-inflammatory medications, not to be confused with muscle-building anabolic steroids you may have heard about in the news. Each patient will have an equal chance of being in either of the two groups. This study will test the safety and efficacy of methylprednisolone acetate in the treatment of pain and inflammation following total knee replacement.


Condition Intervention
Osteoarthritis
Post-Traumatic Arthritis
Drug: methylprednisolone acetate

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Supportive Care
Official Title: Peri-Articular Injections Containing a Corticosteroid During Total Knee Arthroplasty

Resource links provided by NLM:


Further study details as provided by New Lexington Clinic:

Primary Outcome Measures:
  • Length of hospital stay [ Time Frame: days after surgery ]
  • Knee range of motion [ Time Frame: baseline (preoperative), 6 weeks, 3 months, and one year postoperative ]
  • Knee Society Scores [ Time Frame: Baseline (preoperative), 6 weeks, 3 months, and 1 year postoperative ]
  • Complications such as manipulations under anesthesia, revision surgeries, infections, etc. [ Time Frame: within the first postoperative year ]
  • Amount of pain medication taken per day [ Time Frame: during hospital stay ]
  • Patient satisfaction [ Time Frame: 6 weeks, 3 months, and 1 year postoperative ]

Estimated Enrollment: 100
Study Start Date: March 2006
Estimated Study Completion Date: June 2009
Detailed Description:

Information collected during your office visits:

The patient will be asked for a brief medical history so that we may determine if the patient can participate in the study. A member of our research team will ask the patient a series of questions about his/her knee. The patient will be asked to answer this series of questions a total of 4 times over the course of 1 year. Also, we will record how well the patient can bend and straighten your knee at these 4 office visits. We will have the patient rate the pain in his/her knee and ask the patient if he/she is satisfied with the surgery. If the patients have any complications, those will also be recorded. The patient will also have X-rays taken of the knee at the postoperative follow-up visits. This is the normal routine following total knee replacement. The X-rays will be read by the surgeon to help determine the success of the surgery.

Injection during total knee replacement surgery:

All patients will receive an injection containing bupivicaine HCl, morphine, epinephrine, clonidine, cefuroxime, and normal saline that will be placed directly into the knee during surgery. In addition, approximately half of the patients in the study will also receive methylprednisolone acetate as part of the injection.

Information being collected during your hospital stay:

During the hospital stay, information will be gathered for this study. A physical therapist will measure how well the patient can bend and straighten the knee. The amount of pain medication that was taken at the hospital will be recorded, and the number of days spent in the hospital will also be recorded.

  Eligibility

Ages Eligible for Study:   18 Years to 95 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Between ages of 18 and 95
  • Has elected to undergo total knee replacement

Exclusion Criteria:

  • Allergy to any of the medications used in the protocol
  • History of kidney disease
  • Rheumatoid arthritis
  • Any systemic conditions associated with chronic pain
  • History of deep knee sepsis in the affected extremity
  • Unable to understand the questions used to obtain the Knee Society Score
  • Minors and prisoners will be excluded from the study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00492973

Contacts
Contact: Cale A Jacobs, PhD (859)258-8560 cjaco@lexclin.com

Locations
United States, Kentucky
Lexington Clinic Sports Medicine Center Recruiting
Lexington, Kentucky, United States, 40504
Contact: Cale A Jacobs, PhD     859-258-8560     cjaco@lexclin.com    
Principal Investigator: Cale A Jacobs, PhD            
Principal Investigator: Christian P Christensen, MD            
Sponsors and Collaborators
New Lexington Clinic
St. Joseph's Health Care London
Investigators
Principal Investigator: Cale A Jacobs, PhD New Lexington Clinic
Principal Investigator: Christian P Christensen, MD New Lexington Clinic
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00492973     History of Changes
Other Study ID Numbers: LCO.2006.2
Study First Received: June 25, 2007
Last Updated: June 25, 2007
Health Authority: United States: Institutional Review Board

Keywords provided by New Lexington Clinic:
arthroplasty
replacement
knee

Additional relevant MeSH terms:
Arthritis
Osteoarthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Methylprednisolone acetate
Prednisolone acetate
Methylprednisolone
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone hemisuccinate
Prednisolone phosphate
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Agents
Gastrointestinal Agents
Neuroprotective Agents
Protective Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents

ClinicalTrials.gov processed this record on May 19, 2013